Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Symbol: 002603.SZ
SHZ
19.58
CNYTržní cena dnes
12.0881
Poměr P/E
1.2606
Poměr PEG
32.71B
MRK Cap
- 0.03%
Výnos DIV
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603-SZ) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 8322.47 | 2422.7 | 1050.5 | 1554 | |||||||||||||||
balance-sheet.row.short-term-investments | 2554.79 | 518.4 | 55.3 | 217 | |||||||||||||||
balance-sheet.row.net-receivables | 11259.24 | 2699.6 | 2593.1 | 2102.4 | |||||||||||||||
balance-sheet.row.inventory | 9782.92 | 2021.8 | 1672.7 | 1580.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 631.46 | 110.1 | 285.8 | 222.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 29996.09 | 7254.2 | 5602.1 | 5459.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 26574.19 | 6221.8 | 5745.5 | 4299.1 | |||||||||||||||
balance-sheet.row.goodwill | 228.47 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 3445.29 | 828 | 897.9 | 736.6 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 3673.77 | 828 | 897.9 | 736.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 4655.45 | 830.5 | -54.3 | -216 | |||||||||||||||
balance-sheet.row.tax-assets | 820.62 | 279.9 | 117 | 137.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 4451.29 | 921.8 | 596.6 | 1075.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 40175.32 | 9081.9 | 7302.7 | 6032.9 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 70171.42 | 16336.1 | 12904.8 | 11492.3 | |||||||||||||||
balance-sheet.row.account-payables | 10015.9 | 2060.8 | 1621.2 | 1188.4 | |||||||||||||||
balance-sheet.row.short-term-debt | 3422.6 | 656.3 | 513.9 | 270.2 | |||||||||||||||
balance-sheet.row.tax-payables | 1098.62 | 474 | 123.2 | 133.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 1455.8 | 215.1 | 513 | 10.5 | |||||||||||||||
Deferred Revenue Non Current | 1400.88 | 335 | 357.8 | 328.1 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 263.2 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 1781.83 | 1027.3 | 216.3 | 28.3 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 3119.87 | 555.7 | 872.2 | 330.1 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 54.95 | 15 | 12.5 | 10.5 | |||||||||||||||
balance-sheet.row.total-liab | 23563.79 | 5405.8 | 3832.7 | 2569 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 6682.82 | 1670.7 | 1670.7 | 1203.7 | |||||||||||||||
balance-sheet.row.retained-earnings | 26853.23 | 5989.2 | 4306.2 | 4324.4 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 8524.94 | 989 | 808.9 | 640.9 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.63 | 2283.3 | 2283.3 | 2750.3 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 46627.62 | 10932.2 | 9069.1 | 8919.3 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 70171.42 | 16336.1 | 12904.8 | 11492.3 | |||||||||||||||
balance-sheet.row.minority-interest | -19.99 | -1.9 | 3 | 4.1 | |||||||||||||||
balance-sheet.row.total-equity | 46607.63 | 10930.3 | 9072.2 | 8923.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 70171.42 | - | - | - | |||||||||||||||
Total Investments | 7210.24 | 1348.9 | 1 | 1 | |||||||||||||||
balance-sheet.row.total-debt | 4878.39 | 871.4 | 1026.9 | 270.2 | |||||||||||||||
balance-sheet.row.net-debt | -889.29 | -1032.8 | 31.6 | -1066.8 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 2706.16 | 2356.8 | 1341.6 | 1214.9 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 121.87 | 451.5 | 362.9 | 268.2 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -158.7 | 20.1 | -67.7 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 158.7 | -20.1 | 67.7 | |||||||||||||||
cash-flows.row.change-in-working-capital | -1179.67 | 547.8 | -1309.7 | 24.8 | |||||||||||||||
cash-flows.row.account-receivables | -831.66 | -831.7 | -1280.3 | -668.7 | |||||||||||||||
cash-flows.row.inventory | -348.01 | -348 | -104.7 | -364.9 | |||||||||||||||
cash-flows.row.account-payables | 22.82 | 1886.2 | 55.1 | 1126.1 | |||||||||||||||
cash-flows.row.other-working-capital | -22.82 | -158.7 | 20.1 | -67.7 | |||||||||||||||
cash-flows.row.other-non-cash-items | 245.91 | 131.6 | 133.9 | 78.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1894.27 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -246.9 | -214 | -673.6 | -1144.8 | |||||||||||||||
cash-flows.row.acquisitions-net | -628.54 | 0.4 | 2.4 | 1145.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | -5902.36 | -3461.9 | -451 | -2853.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 4047.54 | 1680.7 | 616.6 | 2957.6 | |||||||||||||||
cash-flows.row.other-investing-activites | 0.36 | 0 | -1.2 | -1144.8 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -2729.91 | -1994.8 | -506.8 | -1040.2 | |||||||||||||||
cash-flows.row.debt-repayment | -1250 | -2200 | -1469.9 | -270 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | -413.64 | -282.7 | -1220.1 | -244.1 | |||||||||||||||
cash-flows.row.other-financing-activites | 1321.67 | 1845.7 | 2387.9 | 490.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -341.96 | -637 | -302.1 | -23.3 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.28 | 1.2 | -0.5 | -2 | |||||||||||||||
cash-flows.row.net-change-in-cash | -663.1 | 857.2 | -280.7 | 520.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 5395.81 | 1810.7 | 953.5 | 1234.2 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6058.9 | 953.5 | 1234.2 | 713.4 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1894.27 | 3487.7 | 528.7 | 1586.2 | |||||||||||||||
cash-flows.row.capital-expenditure | -246.9 | -214 | -673.6 | -1144.8 | |||||||||||||||
cash-flows.row.free-cash-flow | 1647.37 | 3273.8 | -144.9 | 441.4 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 13161.66 | 12532.8 | 10116.8 | 8782.5 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 4867.04 | 4540.6 | 3681 | 3118.4 | |||||||||||||||
income-statement-row.row.gross-profit | 8294.62 | 7992.3 | 6435.8 | 5664.1 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 1074.04 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 235.76 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 3177.48 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 505.39 | 576.9 | 366.6 | 323 | |||||||||||||||
income-statement-row.row.operating-expenses | 4982.24 | 5025.8 | 4758.7 | 4179.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 9849.29 | 9566.4 | 8439.7 | 7297.6 | |||||||||||||||
income-statement-row.row.interest-income | 14.34 | 12.9 | 20.4 | 7 | |||||||||||||||
income-statement-row.row.interest-expense | 36.75 | 33.8 | 34 | 3.8 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 3177.48 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -20.99 | -48.9 | -15.4 | -15.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 505.39 | 576.9 | 366.6 | 323 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -20.99 | -48.9 | -15.4 | -15.6 | |||||||||||||||
income-statement-row.row.interest-expense | 36.75 | 33.8 | 34 | 3.8 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 100.71 | 546.1 | 448.6 | 329.5 | |||||||||||||||
income-statement-row.row.ebitda-caps | 3303.32 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 3202.61 | 2829.6 | 1569.1 | 1438 | |||||||||||||||
income-statement-row.row.income-before-tax | 3181.62 | 2780.6 | 1553.7 | 1422.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 482.98 | 423.8 | 212.1 | 207.5 | |||||||||||||||
income-statement-row.row.net-income | 2706.16 | 2361.8 | 1343.9 | 1218.7 |
Často kladené otázky
Co je Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) celková aktiva?
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) celková aktiva jsou 16336112689.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 4639721722.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.630.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 0.986.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.206.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.243.
Co je Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 2361804714.000.
Jaký je celkový dluh podniku?
Celkový dluh je 871449540.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 5025828583.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 1072618858.000.